Palbociclib is indicated for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with:
• an aromatase inhibitor as initial endocrine-based therapy; or
• fulvestrant in patients with disease progression following endocrine therapy.
from FDA,2022.12
LuciusVersionofPalbociclib:DosageandAdministration,Indications,PrecautionsIndica···【more】
Release date:2025-12-05Recommended:6
Lucius Version of Palbociclib: Dosage and Administration, Indications, Precautio···【more】
Release date:2025-12-02Recommended:14